Synthesis and electrophilic substitutions of novel pyrazolo[1,5-c]-1,2,4- triazolo[4,3-a]pyrimidines

Article abstract of DOI:10.3390/molecules16087081

5-Aryl-7-hydrazino-2-phenylpyrazolo[1,5-c]pyrimidines 1 were used as precursors for the preparation of a new series of 5-aryl-8-phenylpyrazolo[1,5-c] -1,2,4- triazolo[4,3-a]pyrimidines 2. The reactions of 2 with certain electrophilic reagents gave the res

Full text of DOI:10.3390/molecules16087081

Molecules 2011, 16, 7081-7096; doi:10.3390/molecules16087081
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis and Electrophilic Substitutions of Novel
Pyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines
Kamal F.M. Atta
Chemistry Department, Faculty of Science, Alexandria University, Ibrahimia P.O. Box 426,
Alexandria 21321, Egypt; E-Mail: prof.kf_atta@yahoo.com; Tel.: 002035917883; Fax: 002035932488
Received: 30 June 2011; in revised form: 1 August 2011 / Accepted: 4 August 2011 /
Published: 18 August 2011
Abstract: 5-Aryl-7-hydrazino-2-phenylpyrazolo[1,5-c]pyrimidines 1 were used as
precursors for the preparation of a new series of 5-aryl-8-phenylpyrazolo[1,5-c]-1,2,4-
triazolo[4,3-a]pyrimidines 2. The reactions of 2 with certain electrophilic reagents gave
the respective 6-substituted derivatives 3-5 rather than the 7-isomeric products.
Formylation of the key compounds 1 with ethyl formate yielded the formyl derivatives
6. Furthermore, boiling of compounds 1 with acetic acid afforded 7-acetylhydrazino-5-
aryl-2-phenylpyrazolo[1,5-c]pyrimidines 7. Bromination of 7 yielded the dibromo-
derivatives 8, while their iodination and nitration gave the monosubstituted derivatives 9
and 10, respectively. Also, treatment of 1 with boiling acetic anhydride yielded the triacetyl
derivatives 11. The structure of synthesized products was confirmed by elemental analyses,
IR, 1H NMR and MS spectra.
Keywords: pyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines; synthesis; electrophilic
substitution reactions; dehydrative cyclization
1. Introduction
The pyrazolo[1,5-c]pyrimidine ring represents a biologically and synthetically important class
of compounds. Many pyrazolo[1,5-c]pyrimidines are known to possess significant hypnotic,
tranquilizing, fungicidal, insecticidal and antibacterial activities [1-3]. Also, the coordination of
pyrazolo[1,5-c]pyrimidines to transition metal ions such as Cu+2 and Ni+2 enhances their biological
activities [4-7].

7082
Molecules 2011, 16
In the last few decades, the chemistry of 1,2,4-triazoles and their fused heterocyclic derivatives has
received considerable attention owing to their synthetic and effective biological importance. 1,2,4-
Triazole moieties have been incorporated into a wide variety of therapeutically interesting drug
candidates, e.g., triazolam [8], alprazolam [9], etizolam [10], and furacylin [11], including anti-
inflammatories, central nervous system stimulants, sedatives, anti-anxiety compounds, antimicrobial
agents [12-15] and antimycotic ones such as fluconazole, intraconazole, voriconazole [16,17].
The above mentioned therapeutic activity has prompted the present investigation to synthesize the
pyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines ring system 2 and a new series of 7-acetylhydrazino-
5-aryl-2-phenylpyrazolo[1,5-c]pyrimidine derivatives 7.
2. Results and Discussion
Much work from our laboratory has utilized hydrazino heterocycles as raw materials for
the synthesis of various types of heterocyclic compounds [18-21]. In the present investigation, the
target pyrazolotriazolopyrimidine compounds were synthesized from 5-aryl-7-hydrazino-2-phenyl-
pyrazolo[1,5-c]pyrimidines 1a-d that were prepared via a sequence of reactions from ethyl
phenylpropiolate [2,22]. Heating of 1a-d with formic acid under reflux yielded a novel series of 5-aryl-
8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines 2a-d (Scheme 1). The structures of 2a-d
1
were deduced from their spectral analyses. Thus, the H-NMR spectra revealed the presence of
three singlets for the pyrazole ring proton at δH 6.91–7.33 ppm, of the pyrimidine ring proton at δH
7.43–7.44 ppm and of triazole ring proton at δH 8.53–9.00 ppm, in addition to the aromatic ring
protons and the absence of NH signals. The MS spectra also showed a molecular ion peak as a base
peak that indicated the stability of this ring.
The electrophilic substitution reactions of pyrazolotriazolopyrimidines 2a-d such as bromination
with bromine, iodination with iodine monochloride and nitration with nitric and sulfuric acids
in glacial acetic acid gave the respective 5-aryl-6-bromo-, 5-aryl-6-iodo- and 5-aryl-6-nitro-8-
1
phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines 3a-d, 4a-d and 5a-d. Their H-NMR spectra
revealed the absence of signals due to the pyrimidine ring proton and the presence of a pyrazole
ring proton signal at δH 6.81–7.33 ppm and a triazole ring proton singlet at δH 8.52–9.04 ppm,
together with the aromatic proton signals at δH 7.12–8.14 ppm. The structure of these derivatives
were also confirmed from their mass spectral data.
Treatment of 1a-d with boiling ethyl formate afforded 5-aryl-7-formylhydrazino-2-
1
phenylpyrazolo[1,5-c]pyrimidines 6a-d. Their H-NMR spectra showed a new characteristic signal at
δH 7.98–8.08 ppm corresponding to the formyl proton, in addition to the aromatic ring protons at δH
7.20–7.99 ppm, with other characteristic signals; a singlet for the exchangeable two NH protons
which were assigned at δH 4.73–4.80 ppm, a singlet at δH 6.68–6.72 ppm for the pyrazole ring
proton and a singlet at δH 7.19–7.29 ppm for the pyrimidine ring proton.

7083
Molecules 2011, 16
Scheme 1. Synthesis and electrophilic substitution reactions of pyrazolotriazolopyrimidines.
Ar
N
N
N
N
H
H
N
H
1
Ar
Ar
N
N
N
N
N
N
N
N
H
N
H
N
CHO
2
6
H2SO4
HNO3
Br2
ICl
Br
N
I
NO2
Ar
Ar
Ar
N
N
N
N
N
N
N
N
N
N
N
N
N
N
5
4
3
Ar = C6H5- (a), p-Me-C6H4- (b), p-MeO-C6H4- (c), p-Cl-C6H4- (d)
Boiling of hydrazine derivatives 1a-d with acetic acid under reflux afforded 7-acetylhydrazino-5-
aryl-2-phenylpyrazolo[1,5-c]pyrimidines 7a-d (Scheme 2). The structures of 7a-d were confirmed
1
by their H-NMR spectra, which revealed an acetyl group proton singlet at δH 2.04–2.36 ppm, in
addition to the characteristic signals of pyrazole and pyrimidine ring protons, two exchangeable
NH protons and aromatic ring protons. The mass spectra of 7a-d which showed their molecular ion
peaks as a base peak also confirmed the structures.
Next, the electrophilic substitution reaction of 7a-d via bromination with bromine in acetic acid
gave the unexpected dibromo derivatives 8a-d rather than the monobromo derivatives. Their 1H-NMR
spectra showed the absence of the signals of both pyrazole and pyrimidine ring protons and the
presence of acetyl group protons, in addition to the other characteristic signals. These unexpected
obtained products may be due to the excess bromine added to obtain a homogenous reaction mixture.
Iodination and nitration of 7a-d yielded the expected 5-aryl-2-phenyl-3-substituted-pyrazolo[1,5-
c]pyrimidine derivatives 9a-d and 10a-d, respectively . Their 1H-NMR spectra revealed the absence of
pyrazole ring proton and the presence of pyrimidine ring proton at δH 7.18–7.73 ppm as well as the
other characteristic signals.

7084
Molecules 2011, 16
Scheme 2. Synthesis and electrophilic substitution reactions of 7-acetyl-
hydrazinopyrazolopyrimidines.
Furthermore, acetylation of 1a-d with boiling acetic anhydride afforded the triacetyl derivatives
1
11a-d. Their H-NMR spectra revealed the absence of the NH protons of the starting hydrazine
derivatives and the presence of signals at δH 2.42–2.56 ppm corresponding to the three acetyl groups
protons, as well as a singlet at δH 6.87–7.28 ppm for the pyrazole ring proton and a singlet at
δH 7.70–8.24 ppm for the pyrimidine ring proton, in addition to the aromatic ring protons at
δH 6.98–8.05 ppm. The structures of 11a-d were also confirmed by their MS spectra which
showed fragmentation process involving a sequential elimination of two ketene molecules to give the
most stable one (M.+-2CH2CO) as a base peak.
3. Experimental
3.1. General
Melting points were determined on a Kofler Block and are uncorrected. Elemental analyses were
carried out in the Microanalytical Laboratory of the Faculty of Science, Cairo University. The IR

7085
Molecules 2011, 16
spectra of compounds were recorded on a Bruker Tensor 37 Fourier Transform infrared 8400
spectrophotometer using potassium bromide pellets and frequencies are reported in cm−1. The
1H- NMR spectra were recorded on a JEOL JNM ECA 500 MHZ instrument and chemical shifts
δH are given in ppm relative to tetramethylsilane used as internal standard. Mass spectra were
recorded at 70 ev with a GCMS-QP 1000 EX spectrometer. Reactions were routinely followed by
thin layer chromatography (TLC; Merck Kieselgel60-F254 precoated plastic plates). The spots were
detected by iodine. 5-Aryl-7-hydrazino-2- phenylpyrazolo[1,5-c]pyrimidines 1 were prepared from the
respective acetylenic β-diketones as described earlier [2,22].
3.2. Synthesis of Compounds
3.2.1. 5-Aryl-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines 2a-d
A mixture of 5-aryl-7-hydrazino-2-phenylpyrazolo[1,5-c]pyrimidines (1a-d, 1 mmol) and formic
acid (10 mL, 99%) was heated under reflux for 10 h. The mixture was evaporated under reduced
pressure and the obtained residue was triturated with water, filtered, washed with EtOH and
crystallized from EtOH to give the 5-aryl-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines
2a-d as colorless needles.
5,8-Diphenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (2a). Yield 81%, 0.25 g, mp 245–246 °C;
1
IR (υmax, cm−1): 1649 (pyrazole ring C=N), 1580 (triazole ring C=N), and 1476 (C=C); H-NMR
(CDCl3, δH, ppm): 6.91 (s, 1H, pyrazole-H), 7.43 (s, 1H, pyrimidine-H), 7.45–7.64 (m, 8H, aromatic-
H), 8.05 (d, 2H, aromatic-H) and 8.53 (s, 1H, triazole-H); MS, m/z (%) = 312 (M.++1, 100,), 285
(M.+- CN, 4), 283 (M.+-N2, 33), 257 (M.+-CN3, 3), 255 (M.+-CH2N3, 16) and 227 (M.+-CH2N5, 8); Anal.
Calc. for C19H13N5 (311.34): C, 73.30; H, 4.21; N, 22.49%, found: C, 73.27; H, 4.22; N, 22.53%.
8-Phenyl-5-p-tolylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (2b). Yield 76%, 0.25 g, mp
247–248 °C; IR (υmax, cm−1): 1643 (pyrazole ring C=N), 1577 (triazole ring C=N), and 1454 (C=C);
1H NMR (DMSO-d6, δH, ppm): 2.39 (s, 3H, CH3), 7.03 (d, 2H, aromatic-H), 7.26 (s, 1H,
pyrazole-H),7.39–7.51 (m, 5H, aromatic-H), 7.44 (s, 1H, pyrimidine-H), 7.65 (d, 2H, aromatic-H)
and 8.96 (s, 1H, triazole-H); MS, m/z (%) = 327 (M.++2, 17), 325 (M.+, 100), 297 (M.+-N2, 24), 282
(M.+-CH3N2, 8),255 (M.+-C2H4N3, 7) and 227 (M.+-C2H4N5, 10); Anal. Calc. for C20H15N5 (325.37):
C, 73.83; H, 4.65;N, 21.52%, found: C, 73.87; H, 4.62; N, 21.55%.
5-(p-Methoxyphenyl)-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (2c). Yield 74%, 0.25 g,
mp 237–238 °C; IR (υmax, cm−1): 1643 (pyrazole ring C=N), 1587 (triazole ring C=N), and 1454
(C=C); 1H NMR (CDCl3, δH, ppm): 3.92 (s, 3H, CH3), 6.93 (s, 1H, pyrazole-H), 7.10 (d, 2H, aromatic-
H), 7.40–7.48 (m, 3H, aromatic-H), 7.44 (s, 1H, pyrimidine-H), 7.57 (d, 2H, aromatic-H), 8.05 (d,
2H, aromatic-H) and 8.55 (s, 1H, triazole-H); MS, m/z (%) = 343 (M.++2, 15), 341 (M.+, 100), 326
(M.+- CH3, 3), 313(M.+-N2, 10), 299 (M.+-CH2N2, 8), 285 (M.+-C2H4N2, 2) and 270 (M.+-C2H3N2O,
11); Anal. Calc. for C20H15N5O (341.37): C, 70.37; H, 4.43; N, 20.52%, found: C, 70.40; H, 4.40;
N, 20.55%.

7086
Molecules 2011, 16
5-(p-Chlorophenyl)-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (2d). Yield 71%, 0.25 g,
mp 299–300 °C; IR (υmax, cm−1): 1643 (pyrazole ring C=N), 1583 (triazole ring C=N), and 1467
1
(C=C); H NMR (DMSO-d6, δH, ppm): 7.33 (s, 1H, pyrazole-H), 7.43 (s, 1H, pyrimidine-H),
7.44–7.52 (m, 3H, aromatic-H), 7.66 (d, 2H, aromatic-H), 7.79 (d, 2H, aromatic-H), 8.04 (d, 2H,
aromatic-H) and 9.00 (s, 1H, triazole-H); MS, m/z (%) = 347 (M.++1, 52), 345 (M.+-1, 100), 319
(M.+-HCN, 8), 317 (M.+-HN2, 17), 289 (M.+-C2H5N2, 6), 282 (M.+-HClN2, 13), 255 (M.+-C2H4ClN2,
16) and 227 (M.+- C3H6ClN3, 8); Anal. Calc. for C19H12ClN5 (345.79): C, 66.00; H, 3.50; N, 20.25%,
found: C, 59.98; H, 3.50; N, 20.22%.
3.2.2. 5-Aryl-6-bromo-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines 3a-d
A solution of bromine (0.06 mL, 1.2 mmol) in acetic acid (10 mL) was gradually added to a
suspension of 5-aryl-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines 2a-d (1 mmol) in acetic
acid (10 mL) with stirring for 3 h at room temperature. The precipitated 5-aryl-6-bromo-8-
phenylpyrazolo[1,5-c]-1,2,4-triazolo-[4,3-a]pyrimidines 3a-d were filtered, washed with water, dried
and crystallized from EtOH as colorless needles.
6-Bromo-5,8-diphenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (3a). Yield 75%, 0.30 g, mp
235–236 °C; IR (υmax, cm−1): 1640 (pyrazole ring C=N), 1580 (triazole ring C=N), and 1455 (C=C);
1H NMR (CDCl3, δH, ppm): 6.92 (s, 1H, pyrazole-H), 7.43–7.69 (m, 8H, aromatic-H), 8.14 (d,
2H, aromatic-H) and 8.58 (s, 1H, triazole-H); MS, m/z (%) = 390 (M.+, 100), 362 (M.+-N2, 13), 310
(M.+- Br, 2), 282 (M.+-BrN2, 13), 255 (M.+-CHBrN3, 12) and 227 (M.+-CHBrN5, 6); Anal. Calc. for
C19H12BrN5 (390.24): C, 58.48; H, 3.10; N, 17.95%, found: C, 58.52; H, 3.08; N, 17.90%.
6-Bromo-8-phenyl-5-p-tolylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (3b). Yield 75%, 0.30 g,
mp 215–216 °C; IR (υmax, cm−1): 1636 (pyrazole ring C=N), 1578 (triazole ring C=N), and 1421
1
(C=C); H NMR (CDCl3, δH, ppm): 2.49 (s, 3H, CH3), 6.90 (s, 1H, pyrazole-H), 7.41–7.57 (m, 7H,
aromatic-H), 8.14 (d, 2H, aromatic-H) and 8.60 (s, 1H, triazole-H); MS, m/z (%) = 407 (M.++3, 8),
405 (M.++1, 100), 377 (M.+-HCN, 8), 324 (M.+-Br, 2), 281 (M.+-CH3BrN2, 6) and 254
(M.+-C2H4BrN3, 5); Anal. Calc. for C20H14BrN5 (404.26): C, 59.42; H, 3.49; N, 17.32%, found: C,
59.39; H, 3.45; N, 17.27%.
6-Bromo-5-(p-methoxyphenyl)-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (3c). Yield
71%, 0.30 g, mp 213–214 °C; IR (υmax, cm−1): 1632 (pyrazole ring C=N), 1587 (triazole ring C=N),
1
and 1427 (C=C); H NMR (CDCl3, δH, ppm): 3.90 (s, 3H, OCH3), 6.81 (s, 1H, pyrazole-H),7.09 (d,
2H, aromatic-H), 7.44–7.56 (m, 3H, aromatic-H),7.59 (d, 2H, aromatic-H), 8.10 (d, 2H, aromatic-
H) and 8.57 (s, 1H, triazole-H); MS, m/z (%) = 422 (M.++2, 100), 420 (M.+, 80), 405 (M.+-CH3, 3),
391 (M.+- HN2, 8), 378 (M.+-CH2N2, 5), 350 (M.+- C2H4N3, 6), 340 (M.+-Br, 3), 313 (M.+-CHBrN, 4),
281 (M.+- CH3BrN2O, 5) and 269 (M.+-C2H3BrN2O, 13); Anal. Calc. for C20H14BrN5O (420.26): C,
57.16; H, 3.36; N, 16.66%, found: C, 57.20; H, 3.38; N, 16.70%.
6-Bromo-5-(p-chlorophenyl)-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (3d). Yield
71%, 0.30 g, mp 238–239 °C; IR (υmax, cm−1): 1637 (pyrazole ring C=N), 1580 (triazole ring C=N),

7087
Molecules 2011, 16
1
and 1414 (C=C); H NMR (CDCl3, δH, ppm): 6.92 (s, 1H, pyrazole-H), 7.47–7.66 (m, 7H,
aromatic-H), 8.14 (d, 2H, aromatic-H) and 8.55 (s, 1H, triazole-H); MS, m/z (%) = 429 (M.++4, 3),
428 (M.++3, 38), 426 (M.++1, 100), 424 (M.+-1, 76), 398 (M.+-HCN, 11), 317 (M.+-BrN2, 8), 289
(M.+-CH2BrN3, 8), 281 (M.+- HBrClN2, 15), 253 (M.+-C2H5BrClN2, 10) and 226 (M.+-C3H6BrClN3,
7); Anal. Calc. for C19H11BrClN5 (424.68): C, 53.74; H, 2.61; N, 16.49%; found: C, 53.72; H, 2.57; N,
16.50%.
3.2.3. 5-Aryl-6-iodo-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines 4a-d
A solution of iodine monochloride (0.2 g, 1.2 mmol) in acetic acid (10 mL) was gradually added to
a suspension of 5- aryl-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[3,4-a]pyrimidines 2a-d (1mmol) in
acetic acid (10 mL) with stirring for 3 h at room temperature. The reaction mixture was then poured
onto crushed ice and the precipitated 5-aryl-6-iodo-8-phenylpyrazolo[1,5,c]-1,2,4-triazolo[3,4-
a]pyrimidines 4a-d were filtered, washed with water, dried and crystallized from EtOH as colorless
needles.
6-Iodo-5,8-diphenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (4a). Yield 91%, 0.40 g, mp
281–282 °C; IR (υmax, cm-1): 1640 (pyrazole ring C=N), 1575 (triazole ring C=N), and 1405
1
(C=C); H NMR (CDCl3, δH, ppm): 6.94 (s, 1H, pyrazole-H), 7.50-7.69 (m, 8H, aromatic-H),
8.10 (d, 2H, aromatic-H) and 8.61 (s, 1H, triazole-H); MS, m/z (%) = 437 (M.+, 100), 409 (M.+-N2,
5), 310 (M.+-I,7), 282 (M.+-IN2, 10), 242 (M.+-C2H2IN3, 4) and 227 (M.+-C3H5IN3, 8); Anal. Calc.
for C19H12IN5 (437.24): C, 52.19; H, 2.77; N, 16.02%, found: C, 52.17; H, 2.80; N, 16.00%.
6-Iodo-8-phenyl-5-p-tolylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (4b). Yield 89%, 0.40 g,
mp 245–246 °C; IR (υmax, cm−1): 1633 (pyrazole ring C=N), 1576 (triazole ring C=N), and 1416
1
(C=C); H NMR (CDCl3, δH, ppm): 2.49 (s, 3H, CH3), 6.90 (s, 1H, pyrazole-H), 7.41-7.69 (m, 7H,
aromatic-H), 8.08 (d, 2H, aromatic-H) and 8.60 (s, 1H, triazole-H); MS, m/z (%) = 453 (M.++2, 9),
452 (M.++1, 100), 423 (M.+-N2, 5), 325 (M.++1-I, 12), 296 (M.+-IN2, 9) and 269 (M.+-CHIN3, 10);
Anal. Calc. for C20H14IN5 (451.26): C, 53.23; H, 3.13; N, 15.52%, found: C, 53.27; H, 3.15; N,
15.50%.
6-Iodo-5-(p-methoxyphenyl)-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (4c). Yield 85%,
0.40 g, mp 225–226 °C; IR (υmax, cm−1): 1623 (pyrazole ring C=N), 1572 (triazole ring C=N), and
1
1458 (C=C); H NMR (CDCl3, δH, ppm): 3.93 (s, 3H, OCH3), 6.86 (s, 1H, pyrazole-H), 7.12 (d, 2H,
aromatic-H), 7.48–7.51 (m, 3H, aromatic-H), 7.61 (d, 2H, aromatic-H), 8.10 (d, 2H, aromatic-H) and
8.61 (s, 1H, triazole-H); MS, m/z (%) = 470 (M.++3, 3), 468 (M.++1, 100),439 (M.+-N2, 6), 341
(M.++1-I, 12), 313 (M.+-CHIN, 4), 285 (M.+-CHIN3, 7), 269 (M.+-C2H3IN2O, 12) and 255
(M.+- C2H3IN3O, 4); Anal. Calc. for C20H14IN5O (467.26): C, 51.41; H, 3.02; N, 14.99%, found: C,
51.44; H, 3.00; N, 15.02%.
5-(p-Chlorophenyl)-6-iodo-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (4d). Yield 85%,
0.40 g, mp 270–271 °C; IR (υmax, cm−1): 1632 (pyrazole ring C=N), 1576 (triazole ring C=N),
1
and 1410 (C=C); H NMR (DMSO-d6, δH, ppm): 7.02 (s, 1H, pyrazole-H), 7.49–7.54 (m, 3H,

7088
Molecules 2011, 16
aromatic-H), 7.65 (d, 2H, aromatic-H), 7.80 (d, 2H, aromatic-H), 7.92 (d, 2H, aromatic-H) and 9.04
(s, 1H, triazole-H); MS, m/z (%) = 475 (M.++3, 3), 472 (M.+, 100), 443 (M.+-HN2, 3), 345 (M.+-I, 7),
309 (M.+-ClI, 2), 289 (M.+-CH2IN3, 5), 282 (M.+-CHClIN, 8) and 241 (M.+-C2H2ClIN3, 9); Anal.
Calc. for C19H11ClIN5 (471.68): C, 48.38; H, 2.35; N, 14.85%, found: C, 48.40; H, 2.40; N, 14.90%.
3.2.4. 5-Aryl-6-nitro-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines 5a-d
A mixture of nitric acid (d 1.41, 1 mL) and sulfuric acid (d 1.84, 1 mL) in glacial acetic acid
(10 mL) was gradually added to a suspension of 5-aryl-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-
a]pyrimidines 2a-d (1 mmol) in glacial acetic acid (10 mL) with stirring for 3 h at room temperature.
The reaction mixture was then poured onto cold water with stirring and the yellow precipitated
solids were filtered, washed with cold water, dried and crystallized from EtOH to give the title
compounds 5a-d as yellow needles.
6-Nitro-5,8-diphenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (5a). Yield 83%, 0.30 g, mp
241–242 °C; IR (υmax, cm−1): 1649 (pyrazole ring C=N), 1579 (triazole ring C=N), and 1462 (C=C);
1H NMR (CDCl3, δH, ppm): 6.93 (s, 1H, pyrazole-H), 7.40–7.44 (m, 6H, aromatic-H), 7.62 (d,
2H, aromatic-H), 8.03 (d, 2H, aromatic-H) and 8.52 (s, 1H, triazole-H); MS, m/z (%) = 356 (M.+, 7),
326 (M.+-H2N2, 4), 311 (M.++1-NO2, 100), 283 (M.+-CHN2O2, 27), 271 (M.+ +1-CN3O2, 2) and 255
(M.+-CHN4O2, 13); Anal. Calc. for C19H12N6O2 (356.34): C, 64.04; H, 3.39; N, 23.58%, found: C,
64.00; H, 3.40; N, 23.60%.
6-Nitro-8-phenyl-5-p-tolylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (5b). Yield 81%, 0.30 g, mp
243–244 °C; IR (υmax, cm−1): 1643 (pyrazole ring C=N), 1578 (triazole ring C=N), and 1415 (C=C);
1H NMR (CDCl3, δH, ppm): 2.47 (s, 3H, CH3), 6.90 (s, 1H, pyrazole-H), 7.37–7.45 (m, 5H, aromatic-
H), 7.51 (d, 2H, aromatic-H), 8.03 (d, 2H, aromatic-H) and 8.54 (s, 1H, triazole-H); MS, m/z (%) =
370 (M.+, 4), 340 (M.+-H2N2, 2), 325 (M.++1-NO2, 100), 309 (M.+-CH3NO2, 1), 297 (M.+-CHN2O2, 22)
and 269 (M.+-C2H3N3O2, 9); Anal. Calc. for C20H14N6O2 (370.36): C, 64.86; H, 3.81; N, 22.69%,
found: C, 64.90; H, 3.80; N, 22.72%.
5-(p-Methoxyphenyl)-6-nitro-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine (5c), Yield
77%, 0.30 g, mp 250–251 °C; IR (υmax, cm−1): 1637 (pyrazole ring C=N), 1585 (triazole ring C=N),
and 1420 (C=C); 1H NMR (CDCl3, δH, ppm): 3.89 (s, 3H, OCH3), 6.97 (s, 1H, pyrazole-H), 7.45–7.47
(m, 3H, aromatic-H), 7.62 (d, 2H, aromatic-H), 7.79 (d, 2H, aromatic-H), 8.02 (d, 2H, aromatic-H)
and 8.75 (s, 1H, triazole-H); MS, m/z (%) = 388 (M.++2, 15), 387 (M.++1, 100), 356 (M.+-CH2O, 7),
339 (M.+-HNO2, 7), 312 (M.+-CH2N2O2, 4), 310 (M.+-CH4N2O2, 11), 284 (M.+-C3H6N2O2, 5) and 251
(M.+-C7H7N2O, 16); Anal. Calc. for C20H14N6O3 (386.36): C, 62.17; H, 3.65; N, 21.75%, found: C,
62.20; H, 3.61; N, 21.73%.
5-(p-Chlorophenyl)-6-nitro-8-phenylpyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidine
(5d).
Yield
77%, 0.30 g, mp 306–307 °C; IR (υmax, cm−1): 1641 (pyrazole ring C=N), 1583 (triazole ring C=N),
1
and 1416 (C=C); H NMR (DMSO-d6, δH, ppm): 7.33 (s, 1H, pyrazole-H), 7.43 (t, 1H, aromatic-H),
7.50 (t, 2H, aromatic-H), 7.66 (d, 2H, aromatic-H), 7.79 (d, 2H, aromatic-H), 8.03 (d, 2H, aromatic-H)

7089
Molecules 2011, 16
and 8.99 (s, 1H, triazole-H); MS, m/z (%) = 391 (M.+, 3), 349 (M.+-CH2N2, 3), 347 (M.+-N2O, 46),
345 (M.+-NO2, 100), 317 (M.+-N3O2, 17), 289 (M.+-C2H4N3O2, 7), 282 (M.+-C6H5O2, 15), 254 (M.+-
C7H4ClN, 22) and 227 (M.+-C7H3ClN3, 12); Anal. Calc. for C19H11ClN6O2 (390.78): C, 58.40; H, 2.84;
N, 21.51%, found: C, 58.44; H, 2.80; N, 21.53%.
3.2.5. 5-Aryl-7-formylhydrazino-2-phenylpyrazolo[1,5-c]pyrimidines 6a-d
A suspension of 5-aryl-7-hydrazino-2-phenylpyrazolo[1,5-c]pyrimidines (1a-d, 1mmol) and ethyl
formate (5 mL) was heated under reflux for 3 h. The product which separated upon cooling
was filtered, washed with EtOH and crystallized from EtOH to give the title compounds 6a-d as
colorless needles.
7-Formylhydrazino-2,5-Diphenylpyrazolo[1,5-c]pyrimidine (6a). Yield 76%, 0.25 g, mp 177–178 °C;
IR (υmax, cm−1): 3368 (NH), 1700 (C=O), 1624 (pyrazole ring C=N), 1568 (pyrimidine ring C=N), and
1
1455 (C=C); H NMR (CDCl3, δH, ppm): 4.80 (s, 2H, exchangeable 2NH), 6.72 (s, 1H, pyrazole-H),
7.29 (s, 1H, pyrimidine-H), 7.30-7.49 (m, 8H, aromatic-H), 7.98 (d, 2H, aromatic-H) and 8.08 (s, 1H,
CHO); MS, m/z (%) = 330 (M.++1, 2), 302 (M.++1-CO, 100), 286 (M.+-CHNO, 23), 272 (M.+-CHN2O,
81), 257 (M.+-C2H4N2O, 2), 244 (M.+-C2H3N3O, 17) and 228 (M.+-C2H5N4O, 6); Anal. Calc. for
C19H15N5O (329.36): C, 69.29; H, 4.59; N, 21.26%, found: C, 69.30; H, 4.62; N, 21.30%.
7-Formylhydrazino-2-phenyl-5-p-tolylpyrazolo[1,5-c]pyrimidine (6b). Yield 71%, 0.25 g, mp
132–133 °C; IR (υmax, cm−1): 3315 (NH), 1701 (C=O), 1610 (pyrazole ring C=N), 1572 (pyrimidine
ring C=N), and 1447 (C=C); 1H NMR (CDCl3, δH, ppm): 2.42 (s, 3H, CH3), 4.77 (s, 2H, exchangeable
2NH), 6.70 (s, 1H, pyrazole-H), 7.28 (s, 1H, pyrimidine-H), 7.29-7.49 (m, 7H, aromatic-H), 7.96 (d,
2H, aromatic- H) and 7.98 (s, 1H, CHO); MS, m/z (%) = 344 (M.++1, 2), 316 (M.++1-CO, 100),
300 (M.+-CHNO, 33), 286 (M.+-CHN2O, 85), 270 (M.+-C2H5N2O, 4), 259 (M.+-C2H2N3O, 7) and 227
(M.+-C8H6N, 10); Anal. Calc. for C20H17N5O (343.38): C, 69.96; H, 4.99; N, 20.40%, found: C,
70.02; H, 5.02; N, 20.44%
7-Formylhydrazino-5-(p-methoxyphenyl)-2-phenylpyrazolo[1,5-c]pyrimidine (6c). Yield 69%, 0.25 g,
mp 157–158 °C; IR (υmax, cm−1): 3265(NH), 1708 (C=O), 1667 (pyrazole ring C=N), 1585
1
(pyrimidine ring C=N), and 1448 (C=C); H NMR (CDCl3, δH, ppm): 3.87 (s, 3H, OCH3), 4.73 (s,
2H, exchangeable 2NH), 6.68 (s, 1H, pyrazole-H), 7.19 (s, 1H, pyrimidine-H), 7.20–7.46 (m, 3H,
aromatic- H), 7.95–7.97 (m, 4H, aromatic-H), 7.98 (d, 2H, aromatic-H) and 8.00 (s, 1H, CHO); MS,
m/z (%) = 361 (M.++2, 5), 359 (M.+, 30), 332 (M.++1-CO, 100), 316 (M.+-CHNO, 23), 302
(M.+-CHN2O, 78), 287 (M.+-C2H4N2O, 12) and 275 (8, M.+-C2H2N3O); Anal. Calc. for C20H17N5O2
(359.38): C, 66.84; H, 4.77; N, 19.49%, found: C, 66.80; H, 4.82; N, 19.50%.
5-(p-Chlorophenyl)-7-formylhydrazino-2-phenylpyrazolo[1,5-c]pyrimidine (6d). Yield 69%, 0.25 g,
mp 175–176 °C; IR (υmax, cm−1): 3315 (NH), 1700 (C=O), 1615 (pyrazole ring C=N), 1575
(pyrimidine ring C=N), and 1450 (C=C); 1H NMR (CDCl3, δH, ppm): 4.76 (s, 2H, exchangeable 2NH),
6.72 (s, 1H, pyrazole-H), 7.28 (s, 1H, pyrimidine-H), 7.41–7.46 (m, 5H, aromatic-H), 7.95–7.99 (m,
4H, aromatic- H) and 8.00 (s, 1H, CHO); MS, m/z (%) = 361 (M.+-3, 2,), 335 (M.++1-CO, 19), 320

7090
Molecules 2011, 16
(M.+-CHNO, 100), 305 (M.+-CH2N2O, 47), 294 (M.+-C2HN2O, 10), 269 (M.+-C6H6O, 5) and 242
(M.+-C7H7NO, 5); Anal. Calc. for C19H14ClN5O (363.80): C, 62.73; H, 3.88; N, 19.25%, found: C,
62.70; H, 3.90; N, 19.30%.
3.2.6. 7-Acetylhydrazino-5-aryl-2-phenylpyrazolo[1,5-c]pyrimidines 7a-d
5-Aryl-7-hydrazino-2-phenylpyrazolo[1,5-c]pyrimidines 1a-d (1mmol) and glacial acetic acid
(10 mL) was heated at reflux for 3 h. The reaction mixture was poured onto crushed ice and the
product which separated was filtered, washed with water, dried and crystallized from EtOH to give the
title compounds 7a-d as colorless needles.
7-Acetylhydrazino-2,5-diphenylpyrazolo[1,5-c]pyrimidine (7a). Yield 88%, 0.30 g, mp 217–218 °C;
IR (υmax, cm−1): 3150 (NH), 1661 (C=O), 1628 (pyrazole ring C=N), 1568 (pyrimidine ring C=N), and
1
1459 (C=C); H NMR (CDCl3, δH, ppm): 2.21(s, 3H, COCH3), 6.67 (s, 1H, pyrazole-H), 7.21 (s, 1H,
pyrimidine-H), 7.30–7.51 (m, 5H, aromatic-H), 7.84–7.96 (m, 5H, aromatic-H), 8.01 (s, 1H,
exchangeable NH) and 8.48 (s, 1H, exchangeable NHCO); MS, m/z (%) = 343 (M.+, 100), 328
(M.+-CH3, 1), 301 (M.+-COCH2, 59), 286 (M.+-NCOCH3, 18) and 243 (M.+-C3H6N3O, 11); Anal.
Calc. for C20H17N5O (343.38): C, 69.96; H, 4.99; N, 20.40%, found: C, 70.00; H, 5.02; N, 20.43%.
7-Acetylhydrazino-2-phenyl-5-p-tolylpyrazolo[1,5-c]pyrimidine (7b). Yield 83%, 0.30 g, mp
224–225 °C; IR (υmax, cm−1): 3252 (NH), 1659 (C=O), 1618 (pyrazole ring C=N), 1556 (pyrimidine
ring C=N), and 1445 (C=C); 1H NMR (CDCl3, δH, ppm): 2.23(s, 3H, CH3), 2.36 (s, 3H, COCH3), 6.70
(s, 1H, pyrazole-H), 7.19 (d, 2H, aromatic-H), 7.26 (s, 1H, pyrimidine-H), 7.36–7.48 (m, 3H, aromatic-
H), 7.79 (d, 2H, aromatic-H), 7.97 (d, 2H, aromatic-H), 8.14 (s, 1H, exchangeable NH) and 8.31
(s, 1H, exchangeable NHCO); MS, m/z (%) = 358 (M.++1, 100), 315 (M.+-COCH2, 63), 300
(M.+-NCOCH3, 19), 288 (M.+-C3H3NO, 6) and 259 (M.+-C3H4N3O, 5); Anal. Calc. for C21H19N5O
(357.41): C, 70.57; H, 5.36; N, 19.59%, found: C, 70.60; H, 5.32; N, 19.55%.
7-Acetylhydrazino-5-p-methoxyphenyl-2-phenylpyrazolo[1,5-c]pyrimidine (7c). Yield 81%, 0.30 g, mp
193–194 °C; IR (υmax, cm−1): 3283 (NH), 1664 (C=O), 1618 (pyrazole ring C=N), 1564 (pyrimidine
1
ring C=N), and 1448 (C=C); H NMR (CDCl3, δH, ppm): 2.24 (s, 3H, COCH3), 3.78 (s, 3H, OCH3),
6.63 (s, 1H, pyrazole-H), 6.88 (d, 2H, aromatic-H), 7.07 (s, 1H, pyrimidine-H), 7.36–7.50 (m, 3H,
aromatic-H), 7.76 (d, 2H, aromatic-H), 7.91 (d, 2H, aromatic-H), 8.13 (s, 1H, exchangeable NH) and
8.91 (s, 1H, exchangeable NHCO); MS, m/z (%) = 374 (M.++1, 100), 331 (M.+-COCH2, 38), 316
(M.+-NCOCH3, 16), 302 (M.+-NNCOCH3, 56), 287 (M.+-C3H6N2O, 8) and 259 (M.+- C4H8N3O, 19); Anal.
Calc. for C21H19N5O2 (373.41): C, 67.55; H, 5.13; N, 18.76%, found: C, 67.58; H, 5.16; N, 18.80%.
7-Acetylhydrazino-5-p-Chlorophenyl-2-phenylpyrazolo[1,5-c]pyrimidine (7d). Yield 79%, 0.30 g, mp
246–247 °C; IR (υmax, cm−1): 3306 (NH), 1664 (C=O), 1613 (pyrazole ring C=N), 1572 (pyrimidine
1
ring C=N), and 1447 (C=C); H NMR (DMSO-d6, δH, ppm): 2.04 (s, 3H, COCH3), 7.08 (s, 1H,
pyrazole-H), 7.67 (s, 1H, pyrimidine-H), 7.41–7.52 (m, 5H, aromatic-H), 8.09 (d, 2H, aromatic-H),
9.81 (s, 1H, exchangeable NH) and 10.14 (s, 1H, exchangeable NHCO); MS, m/z (%) = 382 (M.++4,

7091
Molecules 2011, 16
1), 381 (M.++3, 4), 379 (M.++1, 44), 378 (M.+, 100), 336 (M.+-COCH2, 65), 320 (M.+-NHCOCH3, 16),
306 (M.+-NNHCOCH3, 77) and 270 (M.+-C2H5ClN2O, 10); Anal. Calc. for C20H16ClN5O (377.83): C,
63.58; H, 4.27; N, 18.54%, found: C, 63.61; H, 4.26; N, 18.60%.
3.2.7. 7-Acetylhydrazino-5-aryl-3,4-dibromo-2--phenylpyrazolo[1,5-c]pyrimidines 8a-d
A solution of bromine (0.12 mL, 2.4 mmol) in acetic acid (10 mL) was gradually added to a
suspension of 7-acetylhydrazino-5-aryl-2-phenylpyrazolo[1,5-c]pyrimidines 7a-d (1 mmol) in acetic
acid (10 mL) with stirring for 3 h at room temperature. The precipitated 7-acetylhydrazino-5-aryl-3,4-
dibromo-2-phenylpyrazolo[1,5-c]pyrimidines 8a-d were filtered, washed with water, dried and
crystallized from EtOH as colorless needles.
7-Acetylhydrazino-3,4-dibromo-2,5-diphenylpyrazolo[1,5-c]pyrimidine (8a). Yield 80%, 0.40 g, mp
229–230 °C; IR (υmax, cm−1): 3451 (NH), 1657 (C=O), 1644 (pyrazole ring C=N), 1560 (pyrimidine
1
ring C=N), and 1439 (C=C); H NMR (CDCl3, δH, ppm): 2.09 (s, 3H, COCH3), 7.44–7.53 (m, 6H,
aromatic-H), 7.63 (d, 2H, aromatic-H), 7.94 (d, 2H, aromatic-H) and 8.01 (s, 2H, exchangeable NH
and exchangeable NHCO); MS, m/z (%) = 505(M.++4, 4), 503 (M.++2, 38), 501 (M.+, 100), 459 (M.+-
COCH2, 80), 444 (M.+-NCOCH3, 14), 429 (M.+-NNHCOCH3, 40), 423 (M.++2-Br, 21), 421 (M.+-Br,
19) and 341 (M.+-Br2, 2); Anal. Calc. for C20H15Br2N5O (501.17): C, 47.93; H, 3.02; N, 13.97%,
found: C, 47.95; H, 3.06; N, 14.00%.
7-Acetylhydrazino-3,4-dibromo-2-phenyl-5-p-tolylpyrazolo[1,5-c]pyrimidine (8b). Yield 77%, 0.40 g,
mp 212–213 °C; IR (υmax, cm−1): 3280 (NH), 1664 (C=O), 1618 (pyrazole ring C=N), 1562
1
(pyrimidine ring C=N), and 1439 (C=C); H NMR (CDCl3, δH, ppm): 2.10 (s, 3H, CH3), 2.40 (s, 3H,
COCH3), 7.46–7.55 (m, 5H, aromatic-H), 7.86 (d, 2H, aromatic-H), 7.93 (d, 2H, aromatic-H), 8.04 (s,
1H, exchangeable NH) and 8.06 (s, 1H, exchangeable NHCO); MS, m/z (%) = 519 (M.++4, 1), 517
(M.++2, 15), 515 (M.+, 33), 473 (M.+-COCH2, 18), 458 (M.+-NCOCH3, 2), 444 (M.+-NNCOCH3, 7),
442 (M.+-NHNHCOCH3, 5), 437 (M.++2-Br, 100), 435 (M.+-Br, 84) and 355 (M.+-Br2, 1); Anal. Calc.
for C21H17Br2N5O (515.20): C, 48.96; H, 3.33; N, 13.59%, found: C, 49.00; H, 3.36; N, 13.60%.
7-Acetylhydrazino-3,4-dibromo-5-(p-methoxyphenyl)-2-phenylpyrazolo[1,5-c]-pyrimidine (8c). Yield
75%, 0.40 g, mp 182–183 °C; IR (υmax, cm−1): 3269 (NH), 1668 (C=O), 1612 (pyrazole ring C=N),
1535 (pyrimidine ring C=N), and 1443 (C=C); 1H NMR (CDCl3, δH, ppm): 2.47 (s, 3H, COCH3), 3.79
(s, 3H, OCH3), 7.48–7.62 (m, 3H, aromatic-H), 7.91 (d, 2H, aromatic-H), 8.04 (d, 2H, aromatic-H),
8.08 (d, 2H, aromatic-H), 10.05 (s, 1H, exchangeable NH) and 10.10 (s, 1H, exchangeable NHCO);
MS, m/z (%) = 535(M.++4, 1), 533 (M.++2, 6), 531 (M.+, 10), 489 (M.+-COCH2, 6), 475 (M.+-NCOCH2,
13), 459 (M.+-NNHCOCH3, 23), 453 (M.++2-Br, 73), 451 (M.+-Br, 61) and 370 (M.++1-Br2, 1); Anal.
Calc. for C21H17Br2N5O2 (531.20): C, 47.48; H, 3.23; N, 13.18%, found: C, 47.50; H, 3.26; N, 13.20%.
7-Acetylhydrazino-5-(p-chlorophenyl)-3,4-dibromo-2-phenylpyrazolo[1,5-c]-pyrimidine (8d). Yield
74%, 0.40 g, mp 226–227 °C; IR (υmax, cm−1): 3267 (NH), 1664 (C=O), 1620 (pyrazole ring C=N),
1
1570 (pyrimidine ring C=N), and 1437 (C=C); H NMR (DMSO-d6, δH, ppm): 2.47 (s, 3H, COCH3),
7.49–7.57 (m, 5H, aromatic-H), 8.04 (d, 2H, aromatic-H), 8.15 (d, 2H, aromatic-H), 10.06 (s, 1H,

7092
Molecules 2011, 16
exchangeable NH) and 10.17 (s, 1H, exchangeable NHCO); MS, m/z (%) = 538 (M.++2, 2), 535
(M.+-1, 4), 493 (M.+- COCH3, 4), 463 (M.+-NHNHCOCH3, 3), 458 (M.++2-Br, 20), 456 (M.+-Br, 100)
and 376 (M.+-Br2, 1); Anal. Calc. for C20H14Br2ClN5O (535.62): C, 44.85; H, 2.63; N, 13.08%, found:
C, 44.81; H, 2.60; N, 13.11%.
3.2.8. 7-Acetylhydrazino-5-aryl-3-iodo-2--phenylpyrazolo[1,5-c]pyrimidines 9a-d
A solution of iodine monochloride (0.2 g, 1.2 mmol) in acetic acid (10 mL) was gradually added to
a suspension of 7-acetylhydrazino-5-aryl-2-phenylpyrazolo[1,5-c]pyrimidines 7a-d (1 mmol) in acetic
acid (10 mL) with stirring for 3 h at room temperature. The reaction mixture was then poured onto
crushed ice and the precipitated 7-acetylhydrazino-5-aryl-3-iodo-2-phenylpyrazolo[1,5-c]pyrimidines
9a-d were filtered, washed with water, dried and crystallized from EtOH as colorless needles.
7-Acetylhydrazino-3-iodo-2,5-diphenylpyrazolo[1,5-c]pyrimidine (9a). Yield 85%, 0.40 g, mp 229–
230 °C; IR (υmax, cm−1): 3433 (NH), 1680 (C=O), 1618 (pyrazole ring C=N), 1549 (pyrimidine ring
1
C=N), and 1438 (C=C); H NMR (DMSO-d6, δH, ppm): 2.05 (s, 3H, COCH3), 7.29–7.80 (m, 10H,
aromatic-H), 7.48 (s, 1H, pyrimidine-H), and 8.06 (s, 2H, exchangeable NHCO and exchangeable
NH); MS, m/z (%) = 469 (M.+, 2), 451 (M.+- H2O, 4), 437 (M.+- CH4O, 2), 343 (M.++1-I, 5), 300 (M.+-
I-CH2CO, 32) and 385 (M.+ - CH3INO, 100); Anal. Calc. for C20H16IN5O (469.28): C, 51.19; H, 3.44;
N, 14.92%, found: C, 51.20; H, 3.40; N, 14.88%.
7-Acetylhydrazino-3-iodo-2-phenyl-5-p-tolylpyrazolo[1,5-c]pyrimidine (9b). Yield 83%, 0.40 g, mp
204–205 °C; IR (υmax, cm−1): 3273 (NH), 1661 (C=O), 1610 (pyrazole ring C=N), 1564 (pyrimidine
ring C=N), and 1433 (C=C); 1H NMR (CDCl3, δH, ppm): 2.26 (s, 3H, CH3), 2.42 (s, 3H, COCH3), 7.18
(s, 1H, pyrimidine-H), 7.28–7.30 (m, 3H, aromatic-H), 7.49–7.52 (m, 4H, aromatic-H), 7.84 (d, 2H,
aromatic-H), 7.97 (s, 1H, exchangeable NH), and 7.99 (s, 1H, exchangeable NHCO); MS, m/z (%) =
484 (M.++1, 83), 441 (M.+-COCH2, 34), 426 (M.+-NCOCH3, 12), 412 (M.+-NNCOCH3, 12), 410 (M.+ -
NHNHCOCH3, 1) and 357 (M.++1- I, 16); Anal. Calc. for C21H18IN5O (483.30): C, 52.19; H, 3.75; N,
14.49%, found: C, 52.50; H, 3.79; N, 14.52%.
7-Acetylhydrazino-3-iodo-5-(p-methoxyphenyl)-2-phenylpyrazolo[1,5-c]-pyrimidine (9c). Yield 80%,
0.40 g, mp 124–125 °C; IR (υmax, cm−1): 3290 (NH), 1711 (C=O), 1610 (pyrazole ring C=N), 1560
1
(pyrimidine ring C=N), and 1448 (C=C); H NMR (CDCl3, δH, ppm): 2.16 (s, 3H, COCH3), 3.87 (s,
3H, OCH3), 6.99–7.49 (m, 7H, aromatic-H), 7.69 (s, 1H, pyrimidine-H), 8.01 (d, 2H, aromatic-H) and
9.28 (s, 2H, exchangeable NH and exchangeable NHCO); MS, m/z (%) = 484 (M.+-CH3, 1), 343 (M.+-
NCOCH2, 3), 373 (M.++1-I, 6) and 372 (M.+- I, 1); Anal. Calc. for C21H18IN5O2 (499.30): C, 50.52; H,
3.63; N, 14.03%. Found: C, 50.55; H, 3.59; N, 14.06%.
7-Acetylhydrazino-5-(p-chlorophenyl)-3-iodo-2-phenylpyrazolo[1,5-c]pyrimidine (9d). Yield 80%,
0.40 g, mp 207–208 °C; IR (υmax, cm−1): 3273 (NH), 1662 (C=O), 1616 (pyrazole ring C=N), 1566
1
(pyrimidine ring C=N), and 1439 (C=C); H NMR (DMSO-d6, δH, ppm): 2.01 (s, 3H, COCH3), 7.14
(d, 2H, aromatic-H), 7.40 (s, 1H, pyrimidine-H), 7.49–7.54 (m, 3H, aromatic-H), 7.68 (d, 1H,
aromatic-H), 7.80 (d, 1H, aromatic-H), 7.98 (d, 2H, aromatic-H),. 10.00 (s, 1H, exchangeable NH), and

7093
Molecules 2011, 16
10.16 (s, 1H, exchangeable NHCO); MS, m/z (%) = 506 (M.++2, 45), 504 (M.+, 100), 463 (M.++2-
COCH3, 22), 461 (M.+-COCH3, 57), 446 (M.+-NHCOCH3, 15), 432 (M.+ -NNHCOCH3, 17), 379
(M.++2-I, 10) and 377 (M.+-I, 24); Anal. Calc. for C20H15ClIN5O (503.72): C, 47.69; H, 3.00; N,
13.90%, found: C, 47.72; H, 2.99; N, 13.92%.
3.2.9. 7-Acetylhydrazino-5-aryl-3-nitro-2-phenylpyrazolo[1,5-c]pyrimidines 10a-d
A mixture of nitric acid (d 1.41, 1 mL) and sulfuric acid (d 1.84, 1 mL) in glacial acetic acid
(10 mL) was gradually added to a suspension of 7-acetylhydrazino-5-aryl-2-phenylpyrazolo[1,5-
c]pyrimidines 7a-d (1 mmol) in glacial acetic acid (10 mL) with stirring for 3 h at room temperature.
The reaction mixture was then poured onto cold water with stirring and the yellow precipitated solid
were filtered, washed with cold water, dried and crystallized from EtOH to give the title compounds
10a-d as yellow needles.
7-Acetylhydrazino-3-nitro-2,5-diphenylpyrazolo[1,5-c]pyrimidine (10a). Yield 77%, 0.30 g, mp 191–
192 °C; IR (υmax, cm−1): 3436 (NH), 1743 (C=O), 1633 (pyrazole ring C=N), 1551 (pyrimidine ring
C=N), and 1462 (C=C); 1H NMR (CDCl3, δH, ppm): 1.90 (s, 3H, COCH3), 7.37 (s, 1H, pyrimidine-H),
7.44–7.68 (m, 6H, aromatic-H), 7.97 (d, 2H, aromatic-H), 8.03 (d, 2H, aromatic-H), 8.46 (s, 1H,
exchangeable NH), and 9.26 (s, 1H, exchangeable NHCO); MS, m/z (%) = 389 (M.++1, 4), 360 (M.+-
CO, 7), 346 (M.+-COCH2, 2), 332 (M.+-NCOCH2, 100), 316 (M.+-NNHCOCH3, 4), 302
(M.+-C3H6N2O, 17), 286 (M.+-C2H2N2O3, 10) and 258 (M.+-C3H4N3O3, 25); Anal. Calc. for
C20H16N6O3 (388.38): C, 61.85; H, 4.15; N, 21.64%, found: C, 61.89; H, 4.12; N, 21.60%.
7-Acetylhydrazino-3-nitro-2-phenyl-5-p-tolylpyrazolo[1,5-c]pyrimidine (10b). Yield 75%, 0.30 g, mp
194–195 °C; IR (υmax, cm−1): 3371 (NH), 1745 (C=O), 1601 (pyrazole ring C=N), 1533 (pyrimidine
1
ring C=N), and 1443 (C=C); H NMR (CDCl3, δH, ppm): 1.96 (s, 3H, CH3), 2.44 (s, 3H, COCH3),
7.30–7.71 (m, 10H, aromatic-H and pyrimidine-H) and 8.44 (s, 2H, exchangeable NH and
exchangeable NHCO); MS, m/z (%) = 403 (M.++1, 2), 402 (M.+, 3), 401 (M.+-1, 16), 374 (M.+-CO, 8)
and 346 (M.+-C2H2NO, 6); Anal. Calc. for C21H18N6O3 (402.41): C, 62.68; H, 4.51; N, 20.88%, found:
C, 62.71; H, 4.50; N, 20.91%.
7-Acetylhydrazino-5-(p-methoxyphenyl)-3-nitro-2-phenylpyrazolo[1,5-c]-pyrimidine (10c). Yield 71%,
0.30 g, mp 132–133 °C; IR (υmax, cm−1): 3464 (NH), 1747 (C=O), 1696 (pyrazole ring C=N), 1531
1
(pyrimidine ring C=N), and 1454 (C=C); H NMR (CDCl3, δH, ppm): 1.81 (s, 3H, COCH3), 3.89 (s,
3H OCH3), 7.00–7.71 (m, 10H, aromatic-H and pyrimidine-H) and 8.43 (s, 2H, exchangeable NH and
exchangeable NHCO); MS, m/z (%) = 420 (M.++2, 1), 358 (M.+-C2H6NO, 1), 334 (M.+ -C3H4N2O, 1)
and 300 (M.+-C2H4N3O3, 3); Anal. Calc. for C21H18N6O4 (418.41): C, 60.28; H, 4.34; N, 20.09%,
found: C, 60.31; H, 4.32; N, 20.13%.
7-Acetylhydrazino-5-(p-chlorophenyl)-3-nitro-2-phenylpyrazolo[1,5-c]-pyrimidine (10d). Yield 71%,
0.30 g, mp 174–175 °C; IR (υmax, cm−1): 3371 (NH), 1749 (C=O), 1597 (pyrazole ring C=N), 1533
(pyrimidine ring C=N), and 1443 (C=C); 1H NMR (CDCl3, δH, ppm): 2.13 (s, 3H, COCH3), 7.34–7.73
(m, 10H, aromatic-H and pyrimidine-H) and 8.45 (s, 2H, exchangeable NH and exchangeable NHCO);

7094
Molecules 2011, 16
MS, m/z (%) = 423 (M.+, 1), 381 (M.+-COCH2, 1), 366 (M.+- NCOCH3, 1), 324 (M.+-C3H5N3O, 1) and
300 (M.+-C6H5NO2, 2); Anal. Calc. for C20H15ClN6O3 (422.82): C, 56.81; H, 3.58; N, 19.88%, found:
C, 56.77; H, 3.61; N, 19.85%.
3.2.10. 7-Triacetylhydrazino-5-aryl-2-phenylpyrazolo[1,5-c]pyrimidines 11a-d
A suspension of 5-aryl-7-hydrazino-2-phenylpyrazolo[1,5-c]pyrimidines 1a-d (1 mmol) in acetic
anhydride (5 mL) was heated under reflux for 1 h and the mixture was cooled and poured onto crushed
ice. The product that separated out was filtered off, washed with water and then dried. It was
crystallized from EtOH to give the title compounds 11a-d as colorlees needles.
7-Triacetylhydrazino-2,5-diphenylpyrazolo[1,5-c]pyrimidine (11a). Yield 83%, 0.35 g, mp 179–180 °C;
IR (υmax, cm−1): 1736 (C=O), 1623 (pyrazole ring C=N), 1542 (pyrimidine ring C=N) and 1458 (C=C);
1H NMR (DMSO-d6, δH, ppm): 2.45 (s,3H, COCH3), 2.48 (s, 3H, COCH3), 2.50 (s, 3H, COCH3), 7.28
(s, 1H, pyrazole-H), 7.44 (t, 2H, aromatic-H), 7.50 (t, 4H, aromatic-H), 7.99 (d, 2H, aromatic-H) , 8.05
(d, 2H, aromatic-H) and 8.24 (s, 1H, pyrimidine-H); MS, m/z (%) = 428 (M.++1, 15), 385
(M.+-CH2CO, 15), 343 (M.+-2 CH2CO, 100), 301 (M.+-3 CH2CO, 65), 286 (M.+- C6H6NO2, 24), 272
(M.+-C6H6N2O2, 88) and 270 (M.+-C6H8N2O2, 26); Anal. Calc. for C24H21N5O3 (427.46): C, 67.44; H,
4.95; N, 16.38%, found: C, 67.40; H, 5.00; N, 16.40%.
7-Triacetylhydrazino-2-phenyl-5-p-tolylpyrazolo[1,5-c]pyrimidine (11b). Yield 80%, 0.35 g, mp
194–195 °C; IR (υmax, cm−1): 1726 (C=O), 1622 (pyrazole ring C=N), 1520 (pyrimidine ring C=N) and
1450 (C=C); 1H NMR (CDCl3, δH, ppm): 2.17(s, 3H, CH3), 2.42 (s,3H, COCH3), 2.54 (s, 3H, COCH3),
2.56 (s, 3H, COCH3),6.90 (s, 1H, pyrazole-H), 7.28 (d, 2H, aromatic-H), 7.42–7.50 (m, 3H, aromatic-
H), 7.72 (s, 1H, pyrimidine-H), 7.87 (d, 2H, aromatic-H) and 7.95 (d, 2H, aromatic-H); MS, m/z (%) =
443 (M.++2, 2), 441 (M.+, 10), 399 (M.+-COCH2, 11), 357 (M.+-2COCH2, 100), 315 (M.+-3COCH2, 44)
and 300 (M.+-C6H7NO3, 21); Anal. Calc. for C25H23N5O3 (441.48): C, 68.01; H, 5.25; N, 15.86%,
found: C, 68.12; H, 5.22; N, 15.81%.
7-Triacetylhydrazino-5-p-methoxyphenyl-2-phenylpyrazolo[1,5-c]pyrimidine (11c). Yield 76%, 0.35 g,
mp 132–133 °C; IR (υmax, cm−1): 1720 (C=O), 1614 (pyrazole ring C=N), 1510 (pyrimidine ring C=N),
and 1448 (C=C); 1H NMR (CDCl3, δH, ppm): 2.53(s, 9H, 3COCH3), 3.86 (s, 3H, OCH3), 6.87 (s, 1H,
pyrazole-H), 6.98 (d, 2H, aromatic-H), 7.41–7.49 (m, 3H, aromatic-H), 7.65 (s, 1H, pyrimidine- H)
and 7.91–7.95 (m, 4H, aromatic-H); MS, m/z (%) = 459 (M.++2, 2), 457 (M.+, 17), 415 (M.+- COCH2,
19), 373 (M.+-2COCH2, 100), 331 (M.+-3COCH2, 39), 316 (M.+-C6H7NO3, 17) and 302
(M.+-C7H9NO3, 41); Anal. Calc. for C25H23N5O4 (457.48): C, 65.63; H, 5.07; N, 15.31%, found: C,
65.51; H, 5.05; N, 15.28%.
7-Triacetylhydrazino-5-p-chlorophenyl-2-phenylpyrazolo[1,5-c]pyrimidine (11d). Yield 76%, 0.35 g,
mp 174–175 °C; IR (υmax, cm−1): 1722 (C=O), 1616 (pyrazole ring C=N), 1533 (pyrimidine ring C=N),
and 1443 (C=C); 1H NMR (CDCl3, δH, ppm): 2.52(s, 3H, COCH3), 2.56 (s, 6H, 2COCH3), 6.91 (s, 1H,
pyrazole-H), 7.41–7.49 (m, 5H, aromatic-H), 7.70 (s, 1H, pyrimidine-H), 7.88 (d, 2H, aromatic-H) and
7.93 (d, 2H, aromatic-H); MS, m/z (%) = 464 (M.++2, 1), 462 (M.+, 5), 420 (M.+-COCH2, 8), 378

7095
Molecules 2011, 16
(M.+-2COCH2, 58), 336 (M.+-3COCH2, 30), 320 (M.+-C6H8NO3, 13) and 306 (M.+-C6H8N2O3, 24); Anal.
Calc. for C24H20ClN5O3 (461.90): C, 62.41; H, 4.36; N, 15.16%, found: C, 62.40; H, 4.32; N, 15.20%.
4. Conclusions
In summary, the strategy for constructing the target compounds started by 5-aryl-7-hydrazino-2-
phenylpyrazolo[1,5-c]pyrimidines 1a-d where the hydrazine moiety can be readily heterocyclized with
one-carbon inserting agents to give the triazole ring fused to the pyrazolopyrimidine skeleton has been
successfully demonstrated.
References
1. Elnagdi, M.H.; Fleita, D.H.; Elmoghayar, M.R.H. Reactions with β-cyanoethylhydrazine—II:
Synthesis of some 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine derivatives. Tetrahedron 1975, 31,
63-67.
2. Marei, M.G.; Mishrikey, M.M.; Aly, D.M. New Synthesis of Pyrazolo(1,5-c)pyrimidines from
Acetylenic β- Diketones. Bull. Chem. Soc. Jpn. 1992, 65, 3419-3422.
3. Zvezdina, E.A.; Zhdanova, M.P.I.; Nechayuk, I.I.; Barchan, A.; Simkina, Y.N.; Buchnaya, T.A.
Investigation of pharmacological properties of some pyridinium salts, pyrazolines and pyrazoles.
Khim. Farm. Zh. 1986, 20, 1328-1331.
4. Marei, M.G.; Hassaan, A.M.A. Nickel(II) and copper(II) complexes of 5-aryl-2-phenyl-6H-
pyrazolo-[1,5-c]pyrimidine-7-thiones. Transition Met. Chem. 1992, 17, 489-490.
5. Grim, J.A.; Petering, H.G. The Antitumor Activity of Cu(II)KTS, the Copper(II) chelate of 3-
ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone). Cancer Res. 1967, 27, 1278-1285.
6. Scovill, J.P.; Klayman, D.L.; Franchino, C.F. 2-Acetylpyridine thiosemicarbazones. 4. Complexes
with transition metals as antimalarial and antileukemic agents. J. Med. Chem. 1982, 25,
1261-1264.
7. Sartorelli, A.C.; Creasey, W.A. Cancer chemotherapy. Ann. Rev. Pharmacol. 1969, 9, 51-72.
8. Brucato, A.; Coppola, A.; Gianguzza, S.P.; Provenzano, M. Triazolam: Characteristics of its
depressive action. Boll. Soc. Ital. Biol. Sper. 1978, 54, 1051-1057.
9. Coffen, D.L.; Fryer, R.I.; Triazolobenzodiazepines. U.S. Patent 3,849,434, 19 November 1974;
[Chem. Abstr. 1975, 82, 73044v].
10. Shiroki, M.; Tahara, T.; Araki, K. Jap. Patent 75100096, 1975; [Chem. Abstr. 1976, 84, 59588k].
11. Povelitsa, F.D.; Gural, A.G. Antibacterial effect of furacriline on Brucella. Antibiotiki 1973, 18,
71-74; [Chem. Abstr. 1973, 78, 93044].
12. Karegoudar, P.; Prasad, D.J.; Ashok, M.; Mahalinga, M.; Poojary, B.; Holla, B.S. Synthesis,
antimicrobial and anti-inflammatory activities of some 1,2,4-triazolo[3,4-b] [1,3,4]thiadiazoles
and 1,2,4-triazolo[3,4-b][1,3,4]thiadiazines bearing trichlorophenyl moiety. Eur. J. Med. Chem.
2008, 43, 808-815.
13. Heindel, N.D.; Reid, J.R. 4-Amino-3-mercapto-4H-1,2,4-triazoles and propargyl aldehydes:
A new route to 3-R-8-aryl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazepines. J. Heterocycl. Chem.
1980, 17, 1087-1088.

7096
Molecules 2011, 16
14. Holla, B.S.; Kalluraya, B.; Sridhar, K.R.; Drake, E.; Thomas, L.M.; Bhandary, K.K.; Levine, M.S.
Synthesis, structural characterization, crystallographic analysis and antibacterial properties of
some nitrofuryl triazolo[3,4-b]-1,3,4-thiadiazine. Eur. J. Med. Chem. 1994, 29, 301-308.
15. Mathew, V.; Keshavayya, J.; Vidya, V.P.; Acharya; Reddy, B.M. Heterocyclic system containing
bridgehead nitrogen atom: Synthesis and pharmacological activities of some substituted 1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazoles. Eur. J. Med. Chem. 2006, 41, 1048-1058.
16. Budavari, S.; O'Neil, M.; Smith, A.; Heckelman, P.; Obenchain, J. The Merck Index an
Encyclopedia of Chemicals, Drugs and Biologicals, 12th ed.; Merck Co. Inc.: Rahway, NJ, USA,
1996.
17. Haber, J. Present status and perspectives on antimycoties with systematic effects. Cas. Lek. Cesk.
2001, 140, 596.
18. Atta, K.F.; El Massry, A.M.; Abdel Hamid, H.; El Ashry, E.S.H.; Amer, A. Synthesis of
4(Pyrazol-3-yl)[1,2,4]triazolo[4,3-a]quinoxalines and tetrazolo analog [I]. J. Heterocycl. Chem.
1994, 31, 549-552.
19. Atta, K.F.M.; Marei, M.G.; Mohamed, F.A.M. Synthesis and reactions of a new series of
1,2,4-triazolo[4,3-c]quinazolines. Heterocycles 2011, 83, 339-349.
20. Atta, K.F.M.; Marei, M.G.; Abd El-Magiad, S.M.; El-Nashar, F.H.A. Annulation and
evaluation of antibacterial activity of the new fused tricyclic(5,5,6)ring system of pyrazolo[1,5-c]-
1,2,4-triazolo[4,3-a]pyrimidines. Heterocycles 2011, 83, 1873-1888.
21. Atta, K.F.M.; El Ashry, E.S.H. Synthesis of 4-(1-phenyl-1H-pyrazol-3-yl)[1,2,4]triazolo[4,3-a]
quinoxalines and their 4-halogenopyrazolyl analogs. J. Heterocycl. Chem. 2011, in press.
22. Marei, M.G.; El-Ghanam, M. Reaction of pyrazolo[1,5-c]pyrimidinethiones with hydrazine:
Synthesis of novel substituted pyrazolo[1,5-c]pyrimidine and pyrazolo[1,5-c]tetrazolo[1,5-
a]pyrimidine derivatives. J. Chem. Res. 1993, 2175-2188.
Sample Availability: Samples of compounds 1-11 are available from the author.
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).